Recent Company News

• 01:24 PM ET May 30, 2025
  

  New XOFIGO (radium-223 dichloride) data in metastatic castration-resistant prostate cancer from Phase III PEACE III trial published in Annals of Oncology (€24.74, 0.00)

• 07:53 PM ET May 29, 2025
  

  Astellas Pharma, Evopoint Biosciences enter exclusive license agreement for XNW27011 (¥1413.5000, 0)

• 04:04 PM ET May 28, 2025
  

  Taysha Gene Therapies announces pivotal Part B trial design details for TSHA-102 in Rett syndrome ($2.44, 0.00)

• 05:11 PM ET May 22, 2025
  

  Astellas Pharma and Pfizer report longer-term follow-up results from open-label extension of Phase 3 ARCHES study (¥1390.5000, 0)

• 02:09 AM ET May 12, 2025
  

  Asia pharma stocks under pressure as Trump eyes executive order cutting drug prices:

• 10:56 PM ET Apr 27, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 02:54 AM ET Apr 25, 2025
  

  Astellas Pharma reports Q4 core profit ¥72.6B vs FactSet ¥50.42B (¥1381.5000, 0)

• 05:22 PM ET Apr 24, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:58 AM ET Apr 24, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:30 PM ET Apr 17, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap